Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Cognitive impairment is prevalent in older age and in patients with depression, which may limit the efficacy of psychotherapy for late-life depression (LLD). We analyzed the effect of age and baseline cognition on the efficacy of psychotherapy in LLD.
Methods: This secondary analysis of a randomized controlled multicenter study included 213 participants (60-92 years) with moderate to severe depression who had received either supportive psychotherapy (SUI) or an LLD-specific cognitive behavioral therapy (LLD-CBT), both of which led to a substantial reduction in depressive symptoms. We examined the influence of age and baseline cognition, assessed with the CERAD-plus neuropsychological battery, on changes in the Geriatric Depression Scale (GDS) at the end of treatment and at 6-month follow-up. Trial registration at ClinicalTrials.gov (NCT03735576) and DRKS (DRKS00013769).
Findings: Baseline cognition was slightly below norms (<1SD), with 15 % of patients meeting criteria for Mild Cognitive Impairment (MCI). GDS change at the end of treatment was not significantly associated with baseline cognition or MCI status, although additional interaction analyses suggest that, in the SUI group, lower baseline cognitive performance was associated with reduced treatment efficacy at follow-up only. Additionally, we found that higher age predicted a smaller reduction in GDS scores both at end-of-treatment and at follow-up in both treatment groups.
Interpretation: Higher age, but not lower cognitive performance, was associated with reduced psychotherapy efficacy. Thus, age-related factors should be considered in psychotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jad.2025.119881 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recommendations for Diagnosing and Quantifying treatment outcomes in clinical trials of compulsive sexual behavior disorder.
Addict Behav Rep
June 2025
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
This article proposes minimum requirements for reporting efficacy in treatment studies of compulsive sexual behavior (CSB). CSB disorder (CSBD) is a condition whose diagnostic criteria were only recently defined by the World Health Organization. Multiple primary and secondary outcomes have been used in treatment trials of CSB, and possible neuropsychological measures have been considered.
View Article and Find Full Text PDFDevelopment of a Social Communication Intervention Mobile App for Adolescents With Autism Spectrum Disorder and Social Communication Disorder: Protocol for a Pilot Randomized Clinical Trial.
JMIR Res Protoc
September 2025
Department of Psychiatry, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Republic of Korea.
Background: Autism spectrum disorder (ASD) and social communication disorder (SCD) are neurodevelopmental disorders characterized by deficits in social communication that hinder social adaptation, with limited pharmacological options for therapy owing to the absence of identified biomarkers. Individuals with ASD or SCD require lifelong interventions tailored to their development stages. However, most existing interventions primarily focus on early childhood, leaving adolescents relatively underserved.
View Article and Find Full Text PDFTesting the Efficacy of a Web-Based Intervention for Loss and Bereavement in Later Life (AgE-health Study): Results From a Randomized Controlled Trial.
J Med Internet Res
September 2025
Institute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Leipzig, Germany.
Background: The loss of a loved one is a common yet stressful event in later life. Internet- and mobile-based interventions have been proposed as an effective treatment approach for individuals with prolonged grief.
Objective: The AgE-health study aimed to investigate the efficacy of an eHealth intervention, trauer@ktiv, in reducing prolonged grief symptoms in a sample of older adults.
Digital Psychological Intervention for Inflammatory Rheumatic Diseases: A Pilot Randomized Clinical Trial.
JAMA Netw Open
September 2025
Department of Psychiatry, Psychosomatics, and Psychotherapy, University of Lübeck, Lübeck, Germany.
Importance: Patients with inflammatory rheumatic diseases (IRDs) frequently experience psychological distress; however, access to psychological support remains limited.
Objective: To investigate the effectiveness of a digital psychological intervention for individuals with IRDs.
Design, Setting, And Participants: Participants aged 18 years or older were recruited across Germany between February 22 and June 4, 2024, if they had been diagnosed with rheumatoid arthritis, psoriatic arthritis, or systemic lupus erythematosus and reported psychological distress and reduced quality of life.
Vortioxetine for Major Depressive Disorder in Children: 12-Week Randomized, Placebo-Controlled Study.
JAACAP Open
September 2025
H. Lundbeck A/S, Copenhagen, Denmark.
Objective: To evaluate efficacy, safety, and tolerability of vortioxetine in children ages 7 to 11 years with major depressive disorder.
Method: Patients meeting criteria for incomplete improvement in depressive symptoms (Children's Depression Rating Scale-Revised [CDRS-R] total score ≥40 plus <40% reduction and Parent Global Assessment Global Improvement score >2) after 4 weeks of single-blind lead-in treatment with a brief psychosocial intervention plus placebo were randomized 1:1:1:1 to 8-week double-blind treatment with brief psychosocial intervention and placebo, vortioxetine 10 mg/day, vortioxetine 20 mg/day, or fluoxetine 20 mg/day. Following preplanned interim analysis, enrollment to fluoxetine was stopped, and patients were randomized 1:1:1 to placebo, vortioxetine 10 mg, or vortioxetine 20 mg.